Bromodomains: A novel target for the anticancer therapy

Area of Science:

• Epigenetics
• Molecular Biology
• Cancer Research

Background:

• Bromodomains are protein readers of post-translational modifications, particularly histone acetylation.
• They play crucial roles in regulating gene expression and cellular functions.
• Dysregulation of bromodomain proteins like BRD2 and BRD4 is implicated in oncogenesis.

Purpose of the Study:

• To review bromodomains as emerging epigenetic targets for cancer therapy.
• To summarize the development and clinical progress of small molecule bromodomain inhibitors.

Main Methods:

• Literature review of bromodomain function and inhibition strategies.
• Analysis of current research on small molecules targeting bromodomain proteins.
• Overview of bromodomain inhibitors in early-stage clinical trials.

Main Results:

• Bromodomains are critical regulators of cell cycle and oncogenic gene expression (e.g., BCL-2, MYC, NF-κB).
• Targeting the interaction between acetyl-lysine residues and bromodomains is a viable therapeutic approach.
• Several small molecule inhibitors targeting bromodomain proteins are under investigation.

Conclusions:

• Bromodomains represent a significant class of novel epigenetic targets for cancer treatment.
• Inhibitors targeting bromodomain proteins show potential for regulating pathological gene expression.
• Further clinical development of bromodomain inhibitors is warranted for cancer therapy.